GPT and fatty liver disease: Both groups showed improvements in triglycerides, AST, ALT, AST/ALT ratio, and ALP levels, but only the placebo group reached statistical significance (all p < 0.05).Although BMI decreased significantly in the probiotic group, no significant difference was found compared to placebo (p > 0.05).Liver steatosis grade in USS improved from stage II–III to stage I in a small non-significant subset of probiotic-treated patients.Transient elastography showed no significant fibrosis improvement in either group (p > 0.05).